American Society of Clinical Oncology (ASCO) 2023 Annual Meeting
ASCO 2023 Prostate Cancer
- ASCO 2023: Digital Histopathology-Based Multimodal Artificial Intelligence Scores Predict Risk of Progression in a Randomized Phase III Trial in Patients with Nonmetastatic Castration-Resistant Prostate Cancer
- ASCO 2023: Timing of PARP Inhibition for Prostate Cancer with Defects in Homologous Recombination Repair
- ASCO 2023: A Multi-Center Natural History Study of Precision-Based Genomics in Prostate Cancer
- ASCO 2023: Exercise to Enhance Cardiovascular Health Among Black Patients with Prostate Cancer with Androgen Deprivation Therapy: The POWER Trial
- ASCO 2023: Technology-Enhanced Acceleration of Germline Evaluation for Therapy (TARGET): Results of a Randomized Controlled Trial of a Pretest Patient-Driven Webtool vs. Genetic Counseling for Prostate Cancer Germline Testing
ASCO 2023 Bladder Cancer
- ASCO 2023: Discussant: THOR – Results of Erdafitinib versus Chemotherapy in Patients with Advanced or Metastatic Urothelial Cancer with Select Fibroblast Growth Factor Receptor Alterations
- ASCO 2023: Phase 3 THOR Study: Results of Erdafitinib Versus Chemotherapy in Patients with Advanced or Metastatic Urothelial Cancer with Select Fibroblast Growth Factor Receptor Alterations
- ASCO 2023: Activity of Cabozantinib plus Durvalumab in Patients with Advanced Urothelial Carcinoma or Non-UC Variant Histologies After Platinum Chemotherapy: Interim Results from the Phase 2 ARCADIA Trial
- ASCO 2023: Efficacy of Sacituzumab Govitecan in Locally Advanced or Metastatic Urothelial Cancer by Trophoblast Cell Surface Antigen 2 (Trop-2) Expression
- ASCO 2023: Final Analysis Results from a Multicenter Clinical Study of Tislelizumab Combined with Gemcitabine and Cisplatin as Neoadjuvant Therapy in Patients with cT2-T4aN0M0 MIBC
ASCO 2023 Kidney Cancer
- ASCO 2023: When to Play the Systemic Therapy Card
- ASCO 2023: When Is Stereotactic Ablative Body Radiotherapy an Option?
- ASCO 2023: The Role of Cytoreductive Nephrectomy and Surgical Metastatectomy
- ASCO 2023: Doublet and Triplet Therapy for Metastatic RCC: Factors That Influence Decision-Making
- ASCO 2023: Doublet and Triplet Therapy for Metastatic RCC: The Case for Triplet Therapy
ASCO 2023 Testicular and Penile Cancer
- ASCO 2023: Discussant: Germinating Data for Germ Cell Tumors
- ASCO 2023: Primary RPLND in Seminoma Stage IIA-IIC ≤3cm: Combined Results of the SWENOTECA (Swedish Norwegian Testicular Cancer Group) and Cologne
- ASCO 2023: Molecular Drivers of Organotropism and Cisplatin Resistance in Germ Cell Tumors
- ASCO 2023: Long Term Follow-up Analysis of Plasma miR371 Expression to Detect Early Relapse in Patients with Clinical Stage I Testicular Germ Cell Tumors on Surveillance
- ASCO 2023: Hospital Anxiety and Depression Scale Score Trends Among Testicular Cancer Survivors: A Longitudinal Study
ASCO 2023 Press Releases
ASCO 2023 Upper Tract Urothelial Carcinoma
- ASCO 2023: Final Results from SAUL, a Single-Arm International Real-World Study of Atezolizumab in Patients with Pretreated Locally Advanced/Metastatic UTC
- ASCO 2023: ENLIGHTED: A Phase 3 Multicenter Study to Evaluate the Safety and Efficacy of Padeliporfin Vascular Targeted Photodynamic Therapy in Treatment of Low-Grade UTUC